As the European market navigates through geopolitical uncertainties and fluctuating energy prices, investors are keeping a close eye on resilient economic indicators and solid corporate earnings. In this environment, identifying stocks that may be trading below their estimated value can provide opportunities for those looking to capitalize on potential market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Vitrolife (OM:VITR) | SEK91.80 | SEK181.20 | 49.3% |
| Nexstim (HLSE:NXTMH) | €9.08 | €18.09 | 49.8% |
| Murapol (WSE:MUR) | PLN38.80 | PLN77.07 | 49.7% |
| Mips (OM:MIPS) | SEK378.40 | SEK752.71 | 49.7% |
| Mare Group (BIT:MARE) | €4.95 | €9.89 | 50% |
| Gabriel Holding (CPSE:GABR) | DKK264.00 | DKK521.15 | 49.3% |
| Dustin Group (OM:DUST) | SEK1.74 | SEK3.47 | 49.8% |
| DEUTZ (XTRA:DEZ) | €10.07 | €20.13 | 50% |
| Borregaard (OB:BRG) | NOK156.60 | NOK309.35 | 49.4% |
| BAWAG Group (WBAG:BG) | €173.00 | €345.15 | 49.9% |
Let's take a closer look at a couple of our picks from the screened companies.
Laboratorios Farmaceuticos Rovi (BME:ROVI)
Overview: Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that manufactures, sells, and markets its products in Spain, the European Union, OECD countries, and internationally with a market cap of €3.06 billion.
Operations: The company generates revenue through its marketing segment, which accounts for €474.29 million, and its manufacturing segment, contributing €513.22 million.
Estimated Discount To Fair Value: 45.7%
Laboratorios Farmaceuticos Rovi is trading significantly below its estimated future cash flow value of €110.39, with a current price of €59.9, suggesting it may be undervalued based on cash flows. The company reported strong earnings for the first half of 2026, with net income more than doubling to €84.48 million compared to the previous year. Analysts expect both revenue and profit growth to outpace the broader Spanish market in coming years.
- Our expertly prepared growth report on Laboratorios Farmaceuticos Rovi implies its future financial outlook may be stronger than recent results.
- Click here and access our complete balance sheet health report to understand the dynamics of Laboratorios Farmaceuticos Rovi.
Bonesupport Holding (OM:BONEX)
Overview: Bonesupport Holding AB is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes across the United States, Europe, and internationally, with a market cap of SEK15.02 billion.
Operations: The company's revenue primarily comes from its Pharmaceuticals segment, which generated SEK1.29 billion.
Estimated Discount To Fair Value: 48.3%
Bonesupport Holding is trading at SEK 228, well below its estimated future cash flow value of SEK 440.8, highlighting potential undervaluation based on cash flows. Recent earnings for Q2 2026 showed strong performance with sales reaching SEK 355.72 million and net income increasing to SEK 81.88 million from the previous year. The company has initiated a share repurchase program worth up to SEK 100 million, aiming to enhance shareholder value and optimize capital structure.
- Our earnings growth report unveils the potential for significant increases in Bonesupport Holding's future results.
- Get an in-depth perspective on Bonesupport Holding's balance sheet by reading our health report here.
Robyg (WSE:ROB)
Overview: Robyg S.A. is a Polish company involved in the construction and sale of residential and commercial properties, with a market cap of PLN3.50 billion.
Operations: Revenue Segments (in millions of PLN): Residential properties: 1,200; Commercial properties: 800 In the construction and sale sector in Poland, the company generates revenue primarily from residential properties at PLN1.20 billion and commercial properties at PLN800 million.
Estimated Discount To Fair Value: 26.7%
Robyg, trading at PLN 32.25, is undervalued with an estimated future cash flow value of PLN 44.02. Its earnings are forecast to grow annually by 15.44%, outpacing the Polish market's average growth rate. Recent Q1 results showed significant revenue and net income increases to PLN 316.07 million and PLN 35.89 million respectively from the previous year, reinforcing its strong financial position following a successful IPO raising over PLN 1 billion in June 2026.
- Upon reviewing our latest growth report, Robyg's projected financial performance appears quite optimistic.
- Dive into the specifics of Robyg here with our thorough financial health report.
Next Steps
- Navigate through the entire inventory of 221 Undervalued European Stocks Based On Cash Flows here.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com